Detection of GRM1 gene rearrangements in chondromyxoidfibroma: a comparison of fluorescence in-situ hybridisation, RNA sequencing and immunohistochemical analysis. Chondromyxoidfibroma (CMF) is a rare, benign bone tumour which arises primarily in young adults and is occasionally diagnostically challenging. Glutamate metabotropic receptor 1 (GRM1) gene encodes a metabotropic glutamate receptor and was recently shown to be up-regulated in chondromyxoidfibroma through gene fusion and promoter swapping. The aim of this study was to interrogate cases of CMF for the presence of GRM1 gene rearrangements, gene fusions and GRM1 protein overexpression. Selected cases were subjected to testing by fluorescent in-situ hybridisation (FISH) with a GRM1 break-apart probe, a targeted RNA sequencing method
GRM1 Immunohistochemistry Distinguishes ChondromyxoidFibroma From its Histologic Mimics. Chondromyxoidfibroma (CMF) is a rare benign bone neoplasm that manifests histologically as a lobular proliferation of stellate to spindle-shaped cells in a myxoid background, exhibiting morphologic overlap with other cartilaginous and myxoid tumors of bone. CMF is characterized by recurrent genetic
Chondromyxoidfibroma-like osteosarcoma: a case series and literature review. Chondromyxoidfibroma-like osteosarcoma (CMF-OS) is an exceedingly rare subtype of low-grade central osteosarcoma (LGCO), accounting for up to 10% of cases and making it difficult to diagnose. CMF-OS is frequently misdiagnosed on a radiological examination and biopsy, even after the initial operation. Its treatment directly by the tumor cells under a chondromyxoidfibroma (CMF)-like background. Differential diagnoses based on comprehensive data from CMF, LGCO, chondrosarcoma (CHS), conventional osteosarcoma (COS), etc., are needed. All patients were treated with an operation and chemotherapy, and one patient received additional radiotherapy. Nevertheless, recurrence and metastasis are common in CMF-OS patients
Chondromyxoidfibroma of the temporal bone: A rare case report. Chondromyxoidfibroma (CMF) is a rare form of benign bone tumor and easily misdiagnosed as fibrosarcoma. Hence, to explore the clinical manifestations, diagnostic tests, and therapeutic procedures for temporal bone cartilage myxoid fibroma, it is important to optimize patient treatment and avoid overtreatment. Previous research has
Treatment of cryotherapy and orthotopic transplantation following chondromyxoidfibroma of zygomatic bone: A case report. Chondromyxoid fibrotherma (CMF) is a rare benign cartilage tumor that occurs more frequently in young males at the age of 20 to 30. It occurs more frequently on long bones, but rarely involves craniofacial bones. This study mainly introduced a 30-year-old male with CMF
ChondromyxoidFibroma Arising in Craniofacial Sites: A Clinicopathologic Analysis of 25 Cases. Chondromyxoidfibroma (CMF) is a rare benign tumor, usually arising in the metaphysis of long bones in young adults. Occurrence in craniofacial bones presents a particular diagnostic challenge given its unusual location and resemblance to malignant mimics. We describe the clinicopathologic features
Radiological presentation of chondromyxoidfibroma in the sellar region: A CARE-compliant article and literature review. Chondromyxoidfibroma (CMF) is a rare benign bone neoplasm which often occurs in the lower extremities. Little is known about the radiological and histological presentation of CMF in the sellar region. A 16-year-old Asian male presented to the hospital 12 months ago
Huge chondromyxoidfibroma of the right iliac wing with tremendous soft tissue extensions This report describes a huge chondromyxoidfibroma (CMF) that developed in the right iliac crest and wing. The tumour is rare, perhaps the rarest of all bone tumours, and its occurrence in the iliac crest and wing of a 63-year-old male is extraordinarily uncommon. The patient complained of gradual onset
Long-lasting chondromyxoidfibroma of the zygoma: A rare case report and review of literature Chondromyxoidfibroma (CMF) is a benign tumor which usually occurs in skeletal long bones. Its presence in zygoma is extremely rare. The patient was a 47-year-old female, with chief complaint of painful swelling in the left side of zygoma since 1 month ago after a long-lasting painless swelling for about
Clinical and therapeutic characteristics associated with chondromyxoidfibroma in jaws: systematic review PROSPERO International prospective register of systematic reviews Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information
Imaging features of chondromyxoidfibroma: report of 15 cases and literature review Chondromyxoidfibroma (CMF) is a rare benign bony tumour. Our objectives are three-fold: first, comparing MRI, conventional radiography (CR) and CT characteristics of CMF; second, providing a literature review; and third, summarizing the role of imaging landmarks in the differential diagnosis with other bony
Chondromyxoidfibroma of the sacrum: A case report and literature review Chondromyxoidfibroma (CMF) is an extremely rare, benign cartilaginous tumor that makes up <0.5% of all bone tumors, typically presenting in the second or third decade of life. CMF of the sacrum is exceedingly rare, with only seven documented cases reported in the neurosurgical literature. We report a case of a 35-year-old
ChondromyxoidFibroma of Radius: A Case Report Chondromyxoidfibroma (CMF) is a rare benign cartilaginous tumour accounting to less than 1% of bone tumours. It is most commonly seen in lower extremity involving tibia. CMF of radius is rare. We report a rare case of CMF of proximal radius in a 37-year-old female who presented with swelling and pain over right elbow. Wide local excision of proximal
ChondromyxoidFibroma: A Rare Case Report and Review of Literature Chondromyxoidfibroma (CMF) is one of the rarest benign tumors of cartilaginous origin. It accounts for less than 0.5% of bone tumors and less than two percent of benign bone tumors. It is composed of a mixture of chondroid, myxoid, and fibrous tissues. The diagnosis of CMF depends upon its characteristic histological appearance
ChondromyxoidFibroma of the Skull Base and Calvarium: Surgical Management and Literature Review Chondromyxoidfibroma (CMF) is an exceedingly rare tumor that represents less than 1% of all primary bone neoplasms. Occurrence in the facial and cranial bones is extremely rare and frequently misdiagnosed. Case Reports We report two cases of CMF, one in the sphenoclival skull base and the other
Surgical management of a giant sternal chondromyxoidfibroma: a case report A primary chondromyxoidfibroma (CMF) arising from sternum is quite uncommon tumor in thoracic surgery. Removal of giant sternal tumors requires extensive resection of the anterior chest wall, and results in deformity and paradoxical movement. A 40-year-old female presented a progressively enlarging mass of her anterior
GRM1 is upregulated through gene fusion and promoter swapping in chondromyxoidfibroma. Glutamate receptors are well-known actors in the central and peripheral nervous systems, and altered glutamate signaling is implicated in several neurological and psychiatric disorders. It is increasingly recognized that such receptors may also have a role in tumor growth. Here we provide direct evidence of aberrant glutamate signaling in the development of a locally aggressive bone tumor, chondromyxoidfibroma (CMF). We subjected a series of CMFs to whole-genome mate-pair sequencing and RNA sequencing and found that the glutamate receptor gene GRM1 recombines with several partner genes through promoter swapping and gene fusion events. The GRM1 coding region remains intact, and 18 of 20 CMFs (90%) showed